These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

557 related articles for article (PubMed ID: 27179756)

  • 1. Novel dual agonist peptide analogues derived from dogfish glucagon show promising in vitro insulin releasing actions and antihyperglycaemic activity in mice.
    O'Harte FP; Ng MT; Lynch AM; Conlon JM; Flatt PR
    Mol Cell Endocrinol; 2016 Aug; 431():133-44. PubMed ID: 27179756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dogfish glucagon analogues counter hyperglycaemia and enhance both insulin secretion and action in diet-induced obese diabetic mice.
    O'Harte FP; Ng MT; Lynch AM; Conlon JM; Flatt PR
    Diabetes Obes Metab; 2016 Oct; 18(10):1013-24. PubMed ID: 27357054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the insulinotropic and glucose-lowering actions of zebrafish GIP in mammalian systems: Evidence for involvement of the GLP-1 receptor.
    Graham GV; Conlon JM; Abdel-Wahab YH; Gault VA; Flatt PR
    Peptides; 2018 Feb; 100():182-189. PubMed ID: 29157578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A DPP-IV-resistant triple-acting agonist of GIP, GLP-1 and glucagon receptors with potent glucose-lowering and insulinotropic actions in high-fat-fed mice.
    Bhat VK; Kerr BD; Vasu S; Flatt PR; Gault VA
    Diabetologia; 2013 Jun; 56(6):1417-24. PubMed ID: 23503814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential importance of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide 1 receptor signaling for beta cell survival in mice.
    Maida A; Hansotia T; Longuet C; Seino Y; Drucker DJ
    Gastroenterology; 2009 Dec; 137(6):2146-57. PubMed ID: 19766644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apelin-13 analogues show potent in vitro and in vivo insulinotropic and glucose lowering actions.
    O'Harte FPM; Parthsarathy V; Hogg C; Flatt PR
    Peptides; 2018 Feb; 100():219-228. PubMed ID: 29412822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel GLP-1/xenin hybrid peptide improves glucose homeostasis, circulating lipids and restores GIP sensitivity in high fat fed mice.
    Hasib A; Ng MT; Khan D; Gault VA; Flatt PR; Irwin N
    Peptides; 2018 Feb; 100():202-211. PubMed ID: 29412820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.
    Green BD; Gault VA; O'Harte FP; Flatt PR
    Diabetes Obes Metab; 2005 Sep; 7(5):595-604. PubMed ID: 16050953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucagon-related peptides from phylogenetically ancient fish reveal new approaches to the development of dual GCGR and GLP1R agonists for type 2 diabetes therapy.
    Graham GV; Conlon JM; Abdel-Wahab YH; Flatt PR
    Peptides; 2018 Dec; 110():19-29. PubMed ID: 30391422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of stability, cellular, glucose-lowering and appetite supressing effects of oxyntomodulin analogues modified at the N-terminus.
    Lynch AM; Pathak N; Flatt YE; Gault VA; O'Harte FP; Irwin N; Flatt PR
    Eur J Pharmacol; 2014 Nov; 743():69-78. PubMed ID: 25246014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel GIP-oxyntomodulin hybrid peptide acting through GIP, glucagon and GLP-1 receptors exhibits weight reducing and anti-diabetic properties.
    Bhat VK; Kerr BD; Flatt PR; Gault VA
    Biochem Pharmacol; 2013 Jun; 85(11):1655-62. PubMed ID: 23518155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucagon-like peptides-1 from phylogenetically ancient fish show potent anti-diabetic activities by acting as dual GLP1R and GCGR agonists.
    Graham GV; Conlon JM; Abdel-Wahab YH; Flatt PR
    Mol Cell Endocrinol; 2019 Jan; 480():54-64. PubMed ID: 30312651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin.
    Gault VA; O'Harte FP; Harriott P; Mooney MH; Green BD; Flatt PR
    Diabetologia; 2003 Feb; 46(2):222-30. PubMed ID: 12627321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. desHis¹Glu⁹-glucagon-[mPEG] and desHis¹Glu⁹(Lys³⁰PAL)-glucagon: long-acting peptide-based PEGylated and acylated glucagon receptor antagonists with potential antidiabetic activity.
    Irwin N; Franklin ZJ; O'Harte FP
    Eur J Pharmacol; 2013 Jun; 709(1-3):43-51. PubMed ID: 23562625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel dual incretin agonist peptide with antidiabetic and neuroprotective potential.
    Pathak NM; Pathak V; Gault VA; McClean S; Irwin N; Flatt PR
    Biochem Pharmacol; 2018 Sep; 155():264-274. PubMed ID: 30028989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucagon receptor antagonist and GIP agonist combination for diet-induced obese mice.
    McShane LM; Irwin N; O'Flynn D; Franklin ZJ; Hewage CM; O'Harte FP
    J Endocrinol; 2016 Jun; 229(3):319-30. PubMed ID: 27098830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of independent and combined metabolic effects of chronic treatment with (pGlu-Gln)-CCK-8 and long-acting GLP-1 and GIP mimetics in high fat-fed mice.
    Irwin N; Hunter K; Montgomery IA; Flatt PR
    Diabetes Obes Metab; 2013 Jul; 15(7):650-9. PubMed ID: 23388064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Degradation, receptor binding, insulin secreting and antihyperglycaemic actions of palmitate-derivatised native and Ala8-substituted GLP-1 analogues.
    Green BD; Gault VA; Mooney MH; Irwin N; Harriott P; Greer B; Bailey CJ; O'Harte FP; Flatt PR
    Biol Chem; 2004 Feb; 385(2):169-77. PubMed ID: 15101559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Insulin Response to Oral Glucose in GIP and GLP-1 Receptor Knockout Mice: Review of the Literature and Stepwise Glucose Dose Response Studies in Female Mice.
    Ahrén B; Yamada Y; Seino Y
    Front Endocrinol (Lausanne); 2021; 12():665537. PubMed ID: 34122340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of chronic exposure of clonal β-cells to elevated glucose and free fatty acids on incretin receptor gene expression and secretory responses to GIP and GLP-1.
    Pathak V; Vasu S; Flatt PR; Irwin N
    Diabetes Obes Metab; 2014 Apr; 16(4):357-65. PubMed ID: 24164718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.